u/milos_vanhecke

Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.

That is the catalogue certificate rather than the batch-specific one. Same layout, completely different status.

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

FLOW was kidney outcomes and it is the one nobody quotes

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

Correcting my own comment: I attributed that to the GIP arm and the paper attributes it to the GLP-1 arm.

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

Does the lot on the vial match the lot on the page?

ask for the storage condition the stability statement was written against

Relative risk reduction without the baseline rate is uninterpretable. A large relative reduction on a small absolute risk is a small absolute benefit.

Area percent is the peak area of your compound over the total integrated area, at one wavelength, on one gradient. It is a relative measure of what the detector saw, not a mass fraction of the vial.

Asked BCH for the batch-specific certificate and had the full document — batch, date, method line naming the column — inside six hours. That is now my baseline for everybody.

Asked a question here that I thought was stupid and got three papers back. Best thread I have been in on this site.

What was the comparator?

post the whole document, not the headline number

amylin_amy has the distinction right — one is a fraction of the detector signal, the other is a fraction of the mass.

Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.

Yes — the interval is the finding. A point estimate with a wide interval is a hypothesis in a nice font.

registry entry, protocol, publication — three different documents

Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight.

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.

Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.

Ask what the stability statement was written against — temperature, light, and whether it was the lyophilised powder or the reconstituted solution. Those are three different claims.

Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

Not convinced by the linearity assumption. Dose-response in this class is not linear and the trials show it.

the peripheral and central stories are not in competition

Cardiovascular outcome trials are powered for events, not for weight, and are typically run in a different population with different inclusion criteria. Reading a weight number out of one is reading a secondary endpoint.

Asked for the storage condition behind the stability statement. Got it in a sentence. It is a two-line email and almost nobody sends it.

incretin effect first, then everything else in this board makes sense

Started keeping a folder of every certificate I have been sent. The ones that itemise impurities are a small group and they are mostly the same suppliers.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

A confidence interval is the range of effects compatible with the data. Two trials with overlapping intervals have not disagreed, whatever their point estimates look like next to each other.

Disagree that a lower number is automatically worse. A conservative claim that survives testing is worth more than an optimistic one that does not.

Did you get the chromatogram or only the summary line?

Went looking for the registered protocol to see whether the endpoint had changed. It had not, which was reassuring and worth checking.

ask for the storage condition the stability statement was written against

Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.

net peptide content and purity are two different numbers on the same vial